FDA approves gene therapy Luxturna for hereditary blindness

FDA approves gene therapy Luxturna for hereditary blindness

The US Food and Drug Administration just approved the first gene therapy for an inherited disease.

The treatment, called Luxturna, is for Leber congenital amaurosis, a hereditary form of blindness.

It’s a one-time treatment is injected into the retina of the eye, and it could carry a price tag as high as $1 million.

 http://www.businessinsider.com/fda-approves-luxturna-gene-therapy-for-hereditary-blindness-2017-12?utm_source=feedly&utm_medium=referral

FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss

Luxturna is the first gene therapy approved in the U.S. to target a disease caused by mutations in a specific gene

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm

The FDA just approved Luxturna, a gene therapy that can reverse a form of childhood blindness — Quartz

https://qz.com/1161141/the-fda-just-approved-luxturna-a-gene-therapy-that-can-reverse-a-form-of-childhood-blindness/